Ben, Author at Metabolics Pharma

June 20, 2025 – ABSTRACT – ENT-03 Has Additive Weight Loss and Insulin Normalization Effects with Semaglutide in Diet-Induced Obesity (DIO) in Mice

June 20, 2025 – ABSTRACT – ENT-03 Has Additive Weight Loss and Insulin Normalization Effects with Semaglutide in Diet-Induced Obesity (DIO) in Mice
September 22, 2024 – A novel, centrally acting mammalian aminosterol, ENT-03, induces weight loss in obese and lean rodents

September 22, 2024 – A novel, centrally acting mammalian aminosterol, ENT-03, induces weight loss in obese and lean rodents
January 27, 2022 – Enterin KOL Event Replay: Enterin Meets Study Endpoints for Phase 2b (KARMET) Study Involving Patients with Parkinson’s Disease

January 27, 2022 – Enterin KOL Event Replay: Enterin Meets Study Endpoints for Phase 2b (KARMET) Study Involving Patients with Parkinson’s Disease
Hello world!

Hello world!
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
August 10, 2024 – Asymmetric synthesis of ENT-03, the predicted mammalian ortholog of the dog fish shark aminosterol trodusquemine (MSI-1436)

August 10, 2024 – Asymmetric synthesis of ENT-03, the predicted mammalian ortholog of the dog fish shark aminosterol trodusquemine (MSI-1436)
June 24, 2023 – Enterin Presents Data Demonstrating Strong Benefit of ENT-03 on Body Weight, Adiposity and Blood Glucose Vs. Semaglutide in a Diet Induced Obesity Mouse Model

June 24, 2023 – Enterin Presents Data Demonstrating Strong Benefit of ENT-03 on Body Weight, Adiposity and Blood Glucose Vs. Semaglutide in a Diet Induced Obesity Mouse Model
June 20, 2023 – ENT-03, a Centrally Acting Endogenous Spermine Bile Acid with PTP1B Inhibitory Activity has Potent Effects on Metabolism and Weight in a Mouse Model of Diet Induced Obesity (DIO)

June 20, 2023 – ENT-03, a Centrally Acting Endogenous Spermine Bile Acid with PTP1B Inhibitory Activity has Potent Effects on Metabolism and Weight in a Mouse Model of Diet Induced Obesity (DIO)
June 5, 2023 – Enterin Announces the Start of a First-in-Human Study of ENT-03 in Obesity and Type 2 Diabetes

June 5, 2023 – Enterin Announces the Start of a First-in-Human Study of ENT-03 in Obesity and Type 2 Diabetes
February 1, 2023 – Enterin Announces ENT-03 Benefit in MASH

February 1, 2023 – Enterin Announces ENT-03 Benefit in MASH
Jellyfish medical findings

Jellyfish medical findings